Druggable targets for the immunopathy of Alzheimer's disease-Reference-Cited by-同舟云学术

Druggable targets for the immunopathy of Alzheimer's disease

Published:2023 Issue:9 Volume:14 Page:1645-1661
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Weaver Donald F.¹^ORCID

Affiliation:

1. Krembil Research Institute, University Health Network, Department of Chemistry, University of Toronto, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada

Abstract

Decades of research have yet to identify a disease modifying drug for Alzheimer's disease. This review provides an evaluation of the leading twelve druggable targets (microglial and cytokine), addressing the role of neuroinflammation in Alzheimer's.

Funder

Krembil Foundation

Weston Brain Institute

Canadian Institutes of Health Research

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D3MD00096F

Reference152 articles.

1. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention

2. Epidemiology of Alzheimer Disease

3. Brain atrophy in Alzheimer’s Disease and aging

4. The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highly efficient, catalyst-free, one-pot sequential four-component synthesis of novel spiroindolinone-pyrazole scaffolds as anti-Alzheimer agents: in silico study and biological screening;RSC Medicinal Chemistry;2024

2. Drug Design for Alzheimer’s Disease: Biologics vs. Small Molecules;Current Alzheimer Research;2023-12